The results of this study suggest that Medicare Data on Provider Practice and Specialty, which costs less to obtain than from a for-profit data source, can be used to reliably track the cost and quality effects of vertical integration between hospitals and physicians.
By Morgan N. Fredell, Hagop M. Kantarjian, Ya-Chen Shih, Vivian Ho and Binata Mukherjee
Current U.S. health care spending includes many areas of wasted expenditures. In this study, published in Cancer, the authors explore plans to optimize U.S. health care to provide greater benefits to patients: https://bit.ly/2TmeoDg
The authors conducted mobile phone surveys on energy supply, demand and quality in 12 sub-Saharan African countries, finding that current grid and off-grid electricity supply is inadequate to meet consumers' demands.
The winner’s curse — overestimating the value of an asset and therefore overpaying — is often associated with acquisitions of publicly-traded firms but not with private acquisitions. Using an event study methodology for over 22,000 private acquisitions of U.S. firms between 1985 and 2015, the authors examine a possible winner’s curse for such acquisitions, testing variables to determine what characteristics make a private company more likely to overestimate the asset's value.
Every patient with cancer or another life-threatening disease wants the most effective treatment, but drug prices have become staggering. What determines the escalating prices of cancer drugs?
Donald Light, Hagop M. KantarjianSeptember 3, 2013
For both generic and patented cancer drugs, the free-market economy has not worked well. Solutions are needed to maintain reasonable drug prices that allow for corporate profits and are affordable to patients and to the U.S. health care system.
Hagop M. Kantarjian, Leonard A. ZwellingAugust 26, 2013
In a genuine effort to protect patients from adverse events, regulatory burdens and research rigidity in clinical trials have increased to a point at which such protection is outweighing the benefits, and actually harming patients who are unable to be involved in clinical trials.
Hagop M. Kantarjian, David J. Stewart, Leonard A. ZwellingJune 6, 2013
Allowing the producer-dominated market to set drug prices has spiraled the cost of cancer drugs out of control. Drug pricing can be reduced while preserving the profit-making incentive, by linking price to a true measure of quality: preservation and meaningful prolongation of life.